1. Home
  2. WAFD vs COAG Comparison

WAFD vs COAG Comparison

Compare WAFD & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WaFd Inc.

WAFD

WaFd Inc.

HOLD

Current Price

$28.44

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

COAG

Hemab Therapeutics Holdings Inc. Common Stock

SELL

Current Price

$33.78

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WAFD
COAG
Founded
1917
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.9B
IPO Year
1996
2026

Fundamental Metrics

Financial Performance
Metric
WAFD
COAG
Price
$28.44
$33.78
Analyst Decision
Hold
Strong Buy
Analyst Count
4
6
Target Price
$34.50
★ $62.67
AVG Volume (30 Days)
★ 1.1M
360.3K
Earning Date
10-15-2026
11-05-2026
Dividend Yield
★ 3.80%
N/A
EPS Growth
★ 5.20
N/A
EPS
★ 2.45
N/A
Revenue
★ $29,650,000.00
N/A
Revenue This Year
$127.22
N/A
Revenue Next Year
$21.56
N/A
P/E Ratio
$11.62
★ N/A
Revenue Growth
★ 7.79
N/A
52 Week Low
$28.43
$27.38
52 Week High
$39.49
$55.42

Technical Indicators

Market Signals
Indicator
WAFD
COAG
Relative Strength Index (RSI) 26.93 41.76
Support Level N/A $28.46
Resistance Level $33.59 $33.93
Average True Range (ATR) 0.61 2.28
MACD 0.07 0.50
Stochastic Oscillator 1.61 60.92

Price Performance

Historical Comparison
WAFD
COAG

About WAFD WaFd Inc.

WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: